MyFinsight
Home
Blog
About
Income Statement
|
Cash Flow
|
Balance Sheet
|
Ratios
Cash Flow Overview
Free Cash flow
-$5,484,472
Unit: Dollar
Positive Cash Flow Breakdown
Net income (loss)
Accounts payable
Deferred tax expense
Others
Negative Cash Flow Breakdown
Change in fair value of derivati...
Accounts receivable
Inventory
Others
Subscribe for Financial Insights
Page 1
Quarterly
123
Page 1
Cash Flow
2025-12-31
2025-09-30
2025-06-30
Net income (loss)
18,593,806
13,702,407
-5,884,715
Depreciation and amortization
268,662
275,391
275,413
Provision for losses on accounts receivable
134,267
538,650
211,425
Amortization of operating leases - right-of-use assets
119,100
116,207
113,385
Loss on asset disposal
-
-
0
Amortization of finance leases - right-of-use assets
119,473
119,473
119,473
Amortization of debt discount - bonds offering costs
3,545
3,544
3,545
Change in fair value of derivative financial instruments - warrants
11,817,375
7,519,649
-22,109,537
Deferred tax expense
1,478,813
1,677,047
4,884,535
Non-cash compensation through the issuance of employee stock options
45,096
49,918
52,329
Accounts receivable
7,791,917
5,191,903
7,223,068
Inventory
6,934,201
-1,191,794
3,116,352
Prepaid expenses and other current assets
1,926,764
-408,410
-428,454
Security deposits
-
-55,705
-
Accounts payable
3,097,484
-1,664,244
2,131,285
Accrued expenses
-604,521
1,570,561
786,516
Deferred revenue
0
-2,222
-3,334
Lease obligations - operating leases
-119,573
-115,406
-112,586
Net cash provided by operating activities
-5,278,400
5,104,273
14,775,842
Proceeds from disposition of property and equipment
-
-
0
Purchase of property and equipment
206,072
103,334
218,204
Purchase of intangible assets
-
-
0
Net cash used in investing activities
-206,072
-103,334
-218,204
Payment of bond principal
0
140,000
-
Payments of related party loans payable
0
0
4,000,000
Payments on principal on finance lease obligations
96,594
94,360
92,177
Proceeds from exercise of stock options
90,213
150,000
-
Loan payments
27,254
32,108
38,507
Net cash used in financing activities
-33,635
-116,468
-4,130,684
Net change in cash and restricted cash
-5,518,107
4,884,471
10,426,954
Cash and cash equivalents at beginning of period
27,080,586
11,769,161
-
Cash and cash equivalents at end of period
21,562,479
27,080,586
-
Page 1
Unit: Dollar. Numbers labeled with * are estimated quarterly values.
Page 1
Buy us a coffee
Time Plot
Show the time plot by selecting a row from the table.
Cash Flow
Net change in cash
and restricted cash
-$5,518,107
Net income (loss)
$18,593,806
Accounts payable
$3,097,484
Deferred tax expense
$1,478,813
Depreciation and
amortization
$268,662
Provision for losses on
accounts receivable
$134,267
Amortization of finance
leases - right-of-use...
$119,473
Amortization of operating
leases - right-of-use...
$119,100
Non-cash compensation
through the issuance of...
$45,096
Amortization of debt discount
- bonds offering...
$3,545
Proceeds from exercise of
stock options
$90,213
Net cash provided by
operating activities
-$5,278,400
Net cash used in
investing activities
-$206,072
Net cash used in
financing activities
-$33,635
Canceled cashflow
$23,860,246
Canceled cashflow
$90,213
Change in fair value of
derivative financial...
$11,817,375
Purchase of property and
equipment
$206,072
Payments on principal on
finance lease...
$96,594
Accounts receivable
$7,791,917
Inventory
$6,934,201
Prepaid expenses and
other current assets
$1,926,764
Accrued expenses
-$604,521
Lease obligations -
operating leases
-$119,573
Loan payments
$27,254
Buy us a coffee
ELITE PHARMACEUTICALS INC NV (ELTP)
ELITE PHARMACEUTICALS INC NV (ELTP)